MK1775, a selective wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells

Molecular Cancer Therapeutics

Volumn 11, Issue 1, 2012, Pages 174-182

  Kreahling, Jenny M ^a   Gemmer, Jennifer Y ^a   Reed, Damon ^a   Letson, Douglas ^a   Bui, Marilyn ^a   Altiok, Soner ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE 1; HISTONE H3; MK 1775; PROTEIN; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN WEE 1; TYROSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINESIS; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; EX VIVO STUDY; EXPLANT; GENE MUTATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; HISTONES; HUMANS; MITOSIS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855645086     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0529     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. In: Christopher DM, Fletcher K, Krishnan Unni, Fredrik Mertens, editors. Lyon, France: IARC Press; 2002.
3. Loeb DM. Targeted therapies for sarcomas: the next generation of treatments. Electronic Sarcoma Update Newsletter [serial on the Internet] 2007;4. Available from: http://sarcomahelp.org/research-center/targeted- therapies.html.
4. Ludwig J, Trent JC. Targeted therapy of sarcoma. In: Kurzrock R, Markman M, editors. Targeted cancer therapy. New York: Humana Press; 2008. p. 317-29.
5. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82. (Pubitemid 44547808)
6. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80. (Pubitemid 34879334)
7. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34. (Pubitemid 39296599)
8. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997;16:545-54. (Pubitemid 27067784)
9. Perry JA, Kornbluth S. Cdc25 and Wee1: analogous opposites? Cell Div 2007;2:12.
10. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996;134: 963-70. (Pubitemid 26278221)
11. Igarashi M, Nagata A, Jinno S, Suto K, Okayama H. Wee1(+)-like gene in human cells. Nature 1991;353:80-3.
12. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993;12:75-85. (Pubitemid 23042384)
13. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-7.
14. De Witt Hamer PC, Mir SE, Noske DP, Van Noorden CJ, Wurdinger T. WEE1 kinase targeting combined with DNA damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011;17:4200-7.
15. Garcia K, Stumpff J, Duncan T, Su TT. Tyrosines in the kinesin-5 head domain are necessary for phosphorylation by Wee1 and for mitotic spindle integrity. Curr Biol 2009;19:1670-6.
16. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004;15:252-6. (Pubitemid 38262624)
17. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010;122:347-57.
18. Kiviharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH, et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A 2007;104:7211-6.
19. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011;17:2799-806.
20. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009;8:34.
21. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 2010;5:e14335.
24. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
25. Souss T. The 2010-R1 release of the UMD-TP53 mutation database. 2010 [updated 2010 Jul; cited 2010]. Available from: http://p53.free.fr/index.html.
26. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32. (Pubitemid 351264358)
27. Akakura S, Nochajski P, Gao L, Sotomayor P, Matsui S, Gelman IH. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle 2010;9:4656-65.
28. Utani K, Kohno Y, Okamoto A, Shimizu N. Emergence of micronuclei and their effects on the fate of cells under replication stress. PLoS One 2010;5:e10089.
29. Caruso R, Fedele F, Luciano R, Branca G, Parisi C, Paparo D, et al. Mitotic catastrophe in malignant epithelial tumors: the pathologist's viewpoint. Ultrastruct Pathol 2011;35:66-71.
30. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60. (Pubitemid 27510848)
31. Su TT, Sprenger F, DiGregorio PJ, Campbell SD, O'Farrell PH. Exit from mitosis in Drosophila syncytial embryos requires proteolysis and cyclin degradation, and is associated with localized dephosphorylation. Genes Dev 1998;12:1495-503. (Pubitemid 28243634)
32. Anfinsen K, Devesa SS, Bray F, Troisi R, Jonasdottir T, Bruland O, et al. Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005). Cancer Epidemiol Biomarkers Prev 2011;20:1770-7.
33. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-14. (Pubitemid 27449586)
34. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009;27:2536-41.
35. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-84. (Pubitemid 30463549)
36. Tominaga Y, Li C, Wang RH, Deng CX. Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int J Biol Sci 2006;2:161-70. (Pubitemid 43846008)
37. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
38. Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010;9:523-5.
39. Leijen S, Schellens JH, Shapiro G, Pavlick AC, Tibes R, Demuth T, Viscusi J, et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3067).